The primary goals of treatment of Sjögren’s syndrome (SS) are to relieve the hallmark sicca symptoms and minimize the impact and progression of systemic disease manifestations. Although an array…
DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key systemic lupus erythematosus patient populations covering 171 countries…
No disease-modifying therapies are approved to treat primary Sjögren’s syndrome (pSS), a progressive, autoimmune disease characterized by sicca symptoms, which are caused by chronic inflammation…
Introduction:The prevalence of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in Brazil and Mexico is estimated at 1.3 million and is expected to keep growing. The entry of biosimilars…